Patrick Metzger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3569133/publications.pdf

Version: 2024-02-01

1162367 1281420 11 446 8 11 citations h-index g-index papers 12 12 12 613 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations. American Journal of Human Genetics, 2022, 109, 928-943.	2.6	22
2	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers, 2021, 13, 1151.	1.7	27
3	Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid, 2021, 31, 1076-1085.	2.4	96
4	Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. Cell Communication and Signaling, 2021, 19, 123.	2.7	3
5	Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways. Cell Death and Differentiation, 2020, 27, 1878-1895.	5.0	8
6	Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling. Nature Communications, 2020, 11, 5133.	5.8	37
7	Annotation of Human Exome Gene Variants with Consensus Pathogenicity. Genes, 2020, 11, 1076.	1.0	4
8	HIF- $1\hat{l}\pm$ and HIF- $2\hat{l}\pm$ differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nature Communications, 2020, 11, 4111.	5.8	141
9	Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency. Leukemia, 2020, 34, 2673-2687.	3.3	38
10	Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal. Diagnostics, 2020, 10, 93.	1.3	29
11	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. JCO Precision Oncology, 2018, 2, 1-16.	1.5	41